Transcutaneous Magnetic Spinal Cord Stimulation for Freezing of Gait in Parkinson's Disease

University of Sao Paulo General Hospital38 enrolled

Overview

Dopaminergic drugs partially alleviate gait problems in Parkinson's disease, but the effects are not sustained in the long-term. Particularly, the freezing of gait, balance problems and other gait issues directly impacts patients' quality of life. Experimental epidural spinal cord stimulation studies have suggested positive effects on locomotion among PD patients, but the effects of non invasive stimulation have never been explored.

The present study is a randomized, double-blind, placebo-controlled, parallel, phase II clinical trial that will assess the efficacy and safety of transcutaneous magnetic spinal cord stimulation in PD patients who have gait and balance changes refractory to dopaminergic therapy.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Gait Disorders, Neurologic

Interventions

Non-invasive magnetic stimulation of the spinal cordDEVICE

Non-invasive transcutaneous magnetic stimulation of the dorsal spine will be applied by placing a circular magnetic coil (Magventure®️ MagPro®️ R20) on the skin, in the upper thoracic region (chest level T2-T3). The stimulation intensity will represent 100% of the motor threshold. The intermittent theta burst stimulation protocol will consist of 20 stimulation trains, with an interval of 8 seconds between trains, each train will have 20 bursts, and each burst will have 3 pulses at 50 Hz repeated at 5 Hz. In total, 1200 pulses will be applied for 3 minutes and 58 seconds

Coil will not be connected to the stimulation deviceOTHER

coil will not be connected to the stimulation device, and another active coil will be positioned about 15cm behind, far from its field of view, to provide idea from the sound stimulus that is being stimulated

Eligibility

Sex: ALLMin age: 21 YearsMax age: 81 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Men and women (not pregnant) aged between 21 and 80 years old; 2. Participants with idiopathic Parkinson's disease in Hoehn Yahr stages between 2 and 4 (moderate disease) during off-medication, whose primary symptom includes change in gait and / or balance (score equal to or greater than 1 in subitem 2.12 of the MSD scale -UPDRS \["gait and balance"\]). The participant must also present freezing (block) of gait (score equal to or greater than 1 in sub-item 2.13 of the MSD-UPDRS scale - "freezing"). Patients should experience the above symptoms even though they are optimized from the medication point of view. The criteria for being optimized will be defined by a neurologist specialized in movement disorders who will evaluate the case. The presence of freezing will be confirmed through a specific scale (FOG score). 3. Mini-examination of mental status greater than or equal to 24 points; 4. Able to give informed consent in accordance with institutional policies; 5. Able to meet all testing and monitoring requirements, as defined by the study protocol; Exclusion Criteria: 1. Patients with unstabilized psychiatric comorbidities 2. Impossibility to consent to your participation in the study. 3. Patients with uncontrolled infection or other pre-existing uncontrolled medical conditions (eg, decompensated diabetes, high blood pressure, pneumo or symptomatic heart disease). 4. Concomitant treatment with other experimental drugs. 5. Pregnant or breastfeeding women. 6. Presence of chronic pain in the lower limbs. 7. Patients who are unable to walk without assistance (cane, crutch, walker) or help from another person when they are without their medications for Parkinson's disease (off-medication).

Locations (1)

University of São Paulo

São Paulo, São Paulo, Brazil

RECRUITING

Outcomes

Primary Outcomes

TUG

The primary outcome will be the change in gait speed between pre-stimulation and post-stimulation conditions between the two groups (active and placebo) assessed using the 5-meter total Timed Up and Go Test (TUG). Mixel model ANOVA, with TUG as the dependent variable, and time and group as independent variables -'group' would have two levels ('active' and 'placebo'). Our alternative hypothesis is that 'the time vs. group' interaction effect is significant. Then we should use post hoc statistical tests to explore our data further and to compare the effects of active versus placebo at different time levels.

Time frame: Post-stimulation: immediately after the fifth day of stimulation, seven days after the stimulation, twenty-eight days after stimulation.

Secondary Outcomes

Secondary outcomes will be the change on other gait measures, gait speed.

Evaluate the gait speed through measurements obtained through sensors for gait, during the gait of five meters.

Time frame: Baseline, immediately after the fifth day of stimulation, seven days after the stimulation, twenty-eight days after stimulation.

Secondary outcomes will be the effects of stimulation on other gait measures, step length, stride length and step width.

Evaluate step length, stride length and step width through measurements obtained through sensors for gait, during the gait of five meters.

Time frame: Baseline, immediately after the fifth day of stimulation, seven days after the stimulation, twenty-eight days after stimulation.

Secondary outcomes will be the effects of stimulation on other gait measures, cadencia.

Evaluate the cadencia through measurements obtained through sensors for gait, during the gait of five meters.

Time frame: Baseline, immediately after the fifth day of stimulation, seven days after finishing the stimulation, twenty-eight days after finishing the stimulation.

Central Contacts

Rubens G Cury, MD

CONTACT

5511-26617877 rubens_cury@usp.br

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.